Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Mimedx (MDXG) over the last 14 years, with Q3 2025 value amounting to $2.9 million.

  • Mimedx's Change in Account Payables rose 37875.6% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year increase of 31488.33%. This contributed to the annual value of -$1.4 million for FY2024, which is 28007.66% down from last year.
  • Per Mimedx's latest filing, its Change in Account Payables stood at $2.9 million for Q3 2025, which was up 37875.6% from -$668000.0 recorded in Q2 2025.
  • In the past 5 years, Mimedx's Change in Account Payables registered a high of $3.7 million during Q2 2021, and its lowest value of -$3.6 million during Q3 2021.
  • Moreover, its 5-year median value for Change in Account Payables was $283000.0 (2024), whereas its average is $197789.5.
  • Its Change in Account Payables has fluctuated over the past 5 years, first soared by 687857.14% in 2023, then plummeted by 33068.43% in 2024.
  • Quarter analysis of 5 years shows Mimedx's Change in Account Payables stood at $669000.0 in 2021, then crashed by 137.52% to -$251000.0 in 2022, then skyrocketed by 126.69% to $67000.0 in 2023, then skyrocketed by 964.18% to $713000.0 in 2024, then soared by 308.56% to $2.9 million in 2025.
  • Its Change in Account Payables stands at $2.9 million for Q3 2025, versus -$668000.0 for Q2 2025 and $1.5 million for Q1 2025.